From First-in-Human to Real Use: Why MedTech Innovations Stall - Powered by 3PH Alliance/HRCRS-From First-in-Human to Real Use: Why MedTech Innovations Stall

From First-in-Human to Real Use: Why MedTech Innovations Stall - Powered by 3PH Alliance/HRCRS

Video Transcription

Video Summary

The panel discussed the biggest risks for med tech companies moving from early feasibility studies (EFS) to commercialization. Key concerns included delaying FDA engagement, over-celebrating first-in-human success, underestimating funding needs, failing to validate market need, and not proving safety and usability beyond controlled settings. Speakers emphasized that EFS should be a learning phase, not a victory lap, and that teams should use it to identify design, workflow, and clinical issues early.<br /><br />The conversation then focused on how founders can de-risk their technologies before first-in-human studies by ensuring major unmet need, strong team commitment, iterative design, and early regulatory consultation. The panel stressed that technical validation is not the same as market validation.<br /><br />A major theme was the challenge of moving from “cool” to “useful.” To achieve adoption, products must either be truly transformative or clearly improve cost, safety, or workflow enough to overcome hospital inertia. Reimbursement, hospital economics, and value analysis committees were highlighted as major hurdles.<br /><br />Finally, the panel discussed scaling from a few expert sites to broad commercialization. They emphasized robustness of design, training requirements, generalizability across populations and centers, and the need to expand beyond initial physician champions to gather broader feedback and strengthen the evidence package.

Keywords

early feasibility studies

FDA engagement

first-in-human

market validation

med tech commercialization

reimbursement

hospital workflow

scaling adoption